基于网络药理学、分子模拟及实验验证探讨益脑胶囊治疗阿尔茨海默病的作用机制OA
Exploration on the Mechanism of Yinao Capsules in Alzheimer Disease Based on Network Pharmacology,Molecular Simulation,and Experimental Verification
目的 通过网络药理学、分子模拟和分子动力学结合实验验证探讨益脑胶囊治疗阿尔茨海默病(AD)的潜在作用机制.方法 综合运用网络药理学方法筛选益脑胶囊治疗AD的活性成分与潜在靶点,构建药物-成分-靶点网络,对交集靶点进行GO和KEGG通路富集分析,通过分子对接与分子动力学模拟验证核心结合作用.以C57BL/6小鼠为正常组,将APP/PS1转基因小鼠随机分为模型组、盐酸多奈哌齐组(0.65 mg/kg)及益脑胶囊低、高剂量组(351、1 404 mg/kg),并予相应干预,连续60 d.通过新物体识别与Morris水迷宫实验评价小鼠认知能力,HE染色观察海马CA1区神经元形态,ELISA检测血清白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α含量,Western blot检测脑组织CASP3、BCL2蛋白表达.结果 网络药理学分析筛选出益脑胶囊治疗AD的66个活性成分(去氧三尖杉酯碱、人参皂苷Rg5_qt等)及218个潜在靶点,AKT1、IL6、CASP3为核心靶点.GO和KEGG通路富集分析表明,益脑胶囊通过蛋白质磷酸化、与环核苷酸第二信使偶联的G蛋白偶联受体信号通路、ERK1和ERK2级联反应的正向调控等条目及阿尔茨海默病、神经活性配体-受体相互作用、神经退行性疾病通路-多种疾病、细胞凋亡等通路协同干预AD.分子对接与动力学模拟证实β-谷甾醇与GSK3B可稳定结合.动物实验表明,益脑胶囊能显著改善模型小鼠认知功能(P<0.05,P<0.01),降低血清IL-6、TNF-α含量(P<0.05),上调BCL2蛋白表达并抑制CASP3蛋白活化(P<0.05),减少海马CA1区神经元丢失.结论 益脑胶囊通过多成分协同作用,调控AKT1/GSK3β、IL-6/TNF-α等信号节点,抑制神经炎症与细胞凋亡,从而改善AD模型小鼠认知功能与海马病理损伤,其作用涉及AD等多条信号通路.
Objective To investigate the potential mechanism of Yinao Capsules in the treatment of Alzheimer disease(AD)through network pharmacology,molecular simulation,molecular dynamics simulations,and experimental validation.Methods Network pharmacology methods were comprehensively applied to screen active components and potential targets of Yinao Capsules for AD treatment,and a drug-component-target network was constructed.GO and KEGG pathway enrichment analyses were performed on the intersection targets.Molecular docking and molecular dynamics simulations were used to verify binding interactions of core components and targets.Taking C57BL/6 mice as the normal group,APP/PS1 transgenic mice were randomly divided into model group,donepezil hydrochloride group(0.65 mg/kg)and Yinao Capsules low-and high-dosage groups(351 and 1 404 mg/kg),and were intervened for 60 days.Cognitive ability was evaluated using novel object recognition and Morris water maze tests.Hippocampal CA1 neuronal morphology was observed via HE staining.Serum contents of IL-6 and TNF-α were detected by ELISA.Protein expressions of CASP3 and BCL2 in brain tissue were measured by Western blot.Results Network pharmacology identified 66 active components,including deoxyharringtonine and ginsenoside Rg5_qt,and 218 potential targets,with AKT1,IL6,and CASP3 as core targets.The enrichment analysis results of GO and KEGG pathways showed that Yinao Capsules intervened in AD through protein phosphorylation,G protein coupled receptor signal pathway coupled with cyclic nucleotide second messenger,positive regulation of ERK1 and ERK2 cascade reaction and Alzheimer disease,neuroactive ligand receptor interaction,neurodegenerative disease pathway-a variety of diseases,cell apoptosis and other pathways.Molecular docking and dynamics simulations confirmed that β-sitosterol and GSK3B form a stable complex.Animal experiments showed that Yinao Capsules significantly improved cognitive function in mice(P<0.05,P<0.01),reduced serum IL-6 and TNF-α contents(P<0.05),up-regulated BCL2 protein expression and inhibited CASP3 protein activation(P<0.05),and reduced neuronal loss in the hippocampal CA1 region.Conclusion Yinao Capsules can exert synergistic effects through multiple components,regulating key signaling nodes such as AKT1/GSK3β and IL-6/TNF-α,inhibiting neuroinflammation and apoptosis,thereby improving cognitive function and hippocampal pathological damage in AD model mice.Its mechanism involves multiple signaling pathways including AD-related pathways.
余寅丰;王智森;晁桂林;陈君;马东来;马旭伟;梁策
河北中医药大学药学院,河北 石家庄 050200石家庄藏诺药业股份有限公司,河北 石家庄 050035||河北省民族药制剂产业技术研究院,河北 石家庄 050035河北中医药大学药学院,河北 石家庄 050200石家庄藏诺药业股份有限公司,河北 石家庄 050035||河北省民族药制剂产业技术研究院,河北 石家庄 050035河北中医药大学药学院,河北 石家庄 050200||河北省中药组方制剂技术创新中心,河北 石家庄 050091石家庄东方药业股份有限公司,河北 石家庄 050031河北中医药大学药学院,河北 石家庄 050200||河北省中药组方制剂技术创新中心,河北 石家庄 050091
医药卫生
阿尔茨海默病益脑胶囊网络药理学分子对接APP/PS1小鼠神经炎症
Alzheimer diseaseYinao Capsulesnetwork pharmacologymolecular dockingAPP/PS1 miceneuroinflammation
《中国中医药信息杂志》 2026 (9)
27-37,11
河北省省级科技计划(25362501D)河北省中医药管理局科研计划(2021098)河北省高等学校科学研究项目(QN2026454)
评论